A Case Report Published in Frontiers in Veterinary Science
Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – April 29, 2022) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan”) is proud to announce the publication of a case report regarding its compassionate care liposomal-CBD formulation (Innocan’s LPT platform) (the “Treatment“). The Treatment was administered to a 14-year-old dog suffering from severe cervical pain, hip and elbow osteoarthritis and testicular neoplasia. It was reported that the Treatment resulted in decreased pain and improved mobility. The journal, Frontiers in Veterinary Science, is a global, peer-reviewed, open access publication that bridges animal and human health, brings a comparative approach to medical and surgical challenges, and advances innovative biotechnology and therapy.
The Treatment involved a novel cannabidiol (CBD) analgesic, administered to a dog that was cachectic and had hip and elbow osteoarthritis and severe neck pain in addition to a testicular neoplasia. The dog had been previously unsuccessfully treated with a canine osteoarthritic supplement, non-steroidal anti-inflammatory drugs and gabapentin. Therefore, an addition of Innocan’s LPT liposomal CBD injectable formulation was administered subcutaneously and the dog was monitored via: (i) an activity monitoring collar (PetPace); (ii) owner wellbeing questionnaire; (iii) a pain interactive visual analogue scale (iVAS); (iv) blood work and CBD plasma concentrations. One week from the Liposomal-CBD administration and for up to three weeks following the Treatment, the dog had improved and the owner-provided pain scores were reduced from 21 to 10 (on a scale of 40) and iVAS pain scores were reduced from 10 to seven (on a scale of 10). Additionally, collar activity scores were increased from approximately five to 25 (Figure 1). CBD was quantified in the dog’s plasma for at least 28 days after the Treatment.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/122083
Powered by WPeMatico
